Solasodine，BP010W成份之一，抑制肺癌的遷移和侵襲能力

以作者查詢圖書館館藏

、以作者查詢臺灣博碩士

、以作者查詢全國書目

、勘誤回報

、線上人數：21

、訪客IP：3.139.93.242

姓名

屠少華(Shao-Hua Tu) 查詢紙本館藏

畢業系所

系統生物與生物資訊研究所

論文名稱

Solasodine，BP010W成份之一，抑制肺癌的遷移和侵襲能力
(Solasodine, One of BP010W Component, Inhibits Migration and Invasion Ability in Lung Cancer)

相關論文

★ 中草藥BP004誘導管腔A型乳腺癌細胞凋亡	★ 藉由微陣列基因晶片以探討中草藥BP011w對於抑制肺腺癌細胞株爬行及轉移之機制
★ 鑑別可應用在病理與臨床之肺腺癌與鱗狀上皮細胞肺癌的生物標記	★ 中國傳統醫藥蒙古黃耆在HCT116結腸癌細胞體外和體內實驗呈現腫瘤抑制作用
★ 泰莫西芬與BP012W乙醇分離物之協同作用造成強化管狀A型乳腺癌細胞凋亡影響	★ 揭示CEP55基因在大腸直腸癌轉移中所扮演的角色
★ BP016W-新型食道鱗狀上皮細胞癌候選藥物	★ 傳統中藥複方FY001W是三陰性乳腺癌新型的候選藥物
★ BP023W在頭頸癌中的細胞毒性與調控機制	★ 藉由L1000?表達圖譜數據來解釋中醫分類方法中的屬性和歸經
★ 蒙古黃耆對大腸癌影響並降低miR-29a的表現量之研究	★ 利用生物資訊策略找出普濟方內加速傷口癒合的新配方
★ 藉助模塊化網路策略尋找普濟方之治療疾病核心配方	★ 探索 BP010W 的治療潛力:基於雌激素信號通路, 以澳洲茄胺作為抑製劑研究肺癌細胞遷移的綜合分析
★ 大數據分析糖尿病患者使用糖尿病藥物後得病因果關係和風險比較以桃園某地區醫院為例

檔案

[Endnote RIS 格式]

[Bibtex 格式]

[相關文章]

[文章引用]

[完整記錄]

[館藏目錄]

[檢視]

[下載]

本電子論文使用權限為同意立即開放。
已達開放權限電子全文僅授權使用者為學術研究之目的，進行個人非營利性質之檢索、閱讀、列印。
請遵守中華民國著作權法之相關規定，切勿任意重製、散佈、改作、轉貼、播送，以免觸法。

摘要(中)

肺癌具有很高的死亡率和和很低的治癒率，其中最重要的是轉移率非常的高，而放射治療和化學治療都會產生許多的副作用，目前常用於治療肺癌的標靶治療，後期也會產生強烈的抗藥性，因此，我們希望可以找到新的治療，而許多文獻顯示天然藥物可以用來治療癌症，除了毒性較低也會有較低的副作用。經過藥物的篩選找到了中藥BP010W可以抑制肺癌細胞的爬行能力，因此本文選擇BP010W做更深入的研究。我們將BP010W藥物分層，依據乙醇濃度變化量0%、20%、50%和95%，依序得到不同的成分，並發現BP010W 20%和BP010W 50%的分離物有更好的抑制效果。我們也透過利用生物資訊的方法和文獻的參考探討雌激素途徑會影響肺癌的調控，因此我們篩選出中藥BP010W裡的類固醇生物鹼Solasodine，利用HPLC分析顯示Solasodine出現在我們的BP010W 20%和BP010W 50%的分離物中，也經過加藥實驗證明Solasodine會抑制肺癌細胞的爬行能力，接著也利用西方墨點法，證明爬行相關的蛋白被抑制。最後利用爬行實驗證明了雌激素會增加肺癌細胞的爬行能力，我們也將Solasodine和雌激素共同治療，也發現彼此能互相抗衡爬行的能力。所以我們認為Solasodine可能可以當作新的肺癌治療候選藥物。

摘要(英)

Lung cancer has a high mortality rate and a very low cure rate. The most important one is that the Metastasis rate is very high, and both radiotherapy and chemotherapy have many side effects. Currently, it is often used for the Target treatment of lung cancer. It produces strong resistance, so we hope to find new treatments, and many literatures show that natural medicines can be used to treat cancer, with lower toxicity and lower side effects. After drug screening, it was found that Traditional Chinese Medicine BP010W can inhibit the migration ability of lung cancer cells., thus was selected for further research. The column extraction was performed for isolation of prue compounds from BP010W using different concentrations of ethanol, 0%, 20%, 50% and 95%, and we found the concentrations of 20% and 50% have most effective in inhibiting migration of cell. We assay the bioinformatics and literature references, and It is concluded that the estrogen pathway affects the regulation of lung cancer. Therefore, we screened out the steroid alkaloid Solasodine in Chinese medicine BP010W. HPLC analysis showed that Solasodine appeared in our BP010W 20% and BP010W 50% isolates. It was also confirmed by dosing experiments that Solasodine inhibited the migration ability of lung cancer cells, and then used Western blotting to prove that the migration-related proteins were inhibited. Finally, we using the wound-Healing assay to prove that estrogen will increase the migration ability of lung cancer cells, we also treated Solasodine and estrogen together, and found that each other can compete with each other.

關鍵字(中)

★ 肺癌
★ 轉移
★ 中草藥
★ 龍葵
★ 雌激素

關鍵字(英)

★ LL/2(LLC)
★ Solasodine

論文目次

中文摘要 I
Abstract II
圖目錄 V
表目錄 V
補充圖目錄 VIII
補充表目錄 IX
緒論 1
1-1 肺癌 1
1-2 肺癌轉移與治療 3
實驗方法與材料方法 6
2-1 細胞培養 6
2-2 藥物製備 6
2-3 傳統中藥的萃取 7
2-4 Wound-healing assay 細胞爬行實驗 8
2-5 Transwell-assay 細胞侵襲實驗 8
2-6 藥物分離 9
2-7 藥物接合模擬 10
2-8 晶片分析 10
2-9 高效液相色譜 11
2-10 蛋白質提取 11
2-11 西方墨點法 12
2-12 質粒提取 12
2-13 轉染 13
2-14 螢光素酶測定 13
結果 14
3-1 BP010W不同濃度對細胞爬行能力 14
3-1-1 Wound-healing 分析細胞爬行能力 14
3-1-2 Transwell-migration 分析細胞爬行能力 15
3-2 BP010W分離物對細胞爬行能力的影響 16
3-2-1 BP010W逆向管柱層析分離 16
3-2-2 Wound-healing 分析細胞爬行能力 17
3-2-3 Transwell分析細胞爬行能力 18
3-3 生物資訊分析 20
4-3-1 生物晶片 20
3-3-2 晶片分析 21
3-3-3 雌激素信號途徑相關基因的表現 22
3-4 BP010W中有效成分的篩選 27
3-4-1 藥物對接模擬 27
3-4-2 高效液相色譜分析BP010W中成份 32
3-5 Solasodine細胞學實驗 33
3-5-1 Wound-healing分析細胞爬行能力 33
3-5-2 Transwell分析細胞爬行能力 34
3-5-3 西方墨點法分析爬行相關的蛋白質表現 35
3-6 雌激素促進LLC細胞的爬行 37
3-6-1 Wound-healing分析細胞爬行能力 37
3-6-2 螢光素酶測定 38
討論 39
參考文獻 41
補充資料 46

參考文獻

1. Cronin, K. A., Lake , A. J., Scott , S., et al. Annual Report to the Nation on the Status of Cancer, part I: National cancer statistics. Cancer. 2018;124(13):2801-2814.
2. Yanagawa, N., Shiono, S., Abiko, M., et al. New IASLC/ATS/ERS Classification and Invasive Tumor Size are Predictive of Disease Recurrence in Stage I Lung Adenocarcinoma. J Thorac Oncol. 2013;8(5):612-618.
3. Mollberg, N., Surati, M., Demchuk, C., et al. Mind-mapping for lung cancer: towards a personalized therapeutics approach. Advances in Therapy. 2011;28(3):173-194.
4. Murakami , S., Ito , H., Tsubokawa, N., et al. Prognostic value of the new IASLC/ATS/ERS classification of clinical stage IA lung adenocarcinoma. Lung Cancer. 2015;90(2):199-204.
5. Travis , W., Brambilla, E., Noguchi , M, et al. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011;6(2):244-85.
6. Gu , J., Lu , C., Guo , J, et al. Prognostic significance of the IASLC/ATS/ERS classification in Chinese patients-A single institution retrospective study of 292 lung adenocarcinoma. J Surg Oncol. 2013;107(5):474-80.
7. Carr , S., Akerley , W., & Cannon-Albright , L. Genetic Contribution to Nonsquamous, Non-Small Cell Lung Cancer in Nonsmokers. J Thorac Oncol., 2018;13(7):938-945.
8. Faeh, D., Kaufmann, M., Haile, S., & Bopp, M. BMI–mortality association: shape independent of smoking status but different for chronic lung disease and lung cancer. International Journal of COPD. 2018;2018(13):1851-1855.
9. Yu , D., Zheng , W., Johansson , M., et al. Overall and Central Obesity and Risk of Lung Cancer: A Pooled Analysis. J Natl Cancer Inst. 2018;110(8):831-842.
10. Lagerwaard , F., Levendag , P., Nowak , P., et al. Identification of prognostic factors in patients with brain metastases: a review of 1292 patients. Int J Radiat Oncol Biol Phys. 1999;43(4):795-803.
11. Popper, H. Progression and metastasis of lung cancer. Cancer Metastasis Rev. 2016;35:75-91.
12. Kris , M., Natale , R., Herbst , R., et al. T. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA. 2003;290(16):2149-58.
13. Fukuoka , M., Yano , S., Giaccone , G., et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol. 2003;21(12):2237-46.
14. Mitsudomi , T., Morita , S., Yatabe , Y., et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010;11(2):121-8.
15. Dagogo-Jack, I., Brannon , A., Ferris , L., et al. Tracking the Evolution of Resistance to ALK Tyrosine Kinase Inhibitors through Longitudinal Analysis of Circulating Tumor DNA. JCO Precis Oncol. 2018
16. Huang , C., Fong , Y., Lee , C., et al. CCL5 increases lung cancer migration via PI3K, Akt and NF-kappaB pathways. Biochem Pharmacol. 2009;77(5):794-803.
17. Akca , H., Demiray , A., Tokgun , O, etal. Invasiveness and anchorage independent growth ability augmented by PTEN inactivation through the PI3K/AKT/NFkB pathway in lung cancer cells. Lung Cancer. 2011;73(3):302-9.
18. Geiger , B., Bershadsky , A., Pankov , R, et al. Transmembrane crosstalk between the extracellular matrix--cytoskeleton crosstalk. Nat Rev Mol Cell Biol. 2001;2(11):793-805.
19. Raines, E. The extracellular matrix can regulate vascular cell migration, proliferation, and survival: relationships to vascular disease. Int J Exp Pathol. 2000;81(3):173-82.
20. Ryu , B., Lee , H., Kim , S., et al. PF-3758309, p21-activated kinase 4 inhibitor, suppresses migration and invasion of A549 human lung cancer cells via regulation of CREB, NF-κB, and β-catenin signaling. Mol Cell Biochem. 2014;389(1-2):69-77.
21. Legrand , C., Gilles , C., Zahm , J., et al. Airway epithelial cell migration dynamics. MMP-9 role in cell-extracellular matrix remodeling. J Cell Biol. 1999;146(2):517-29.
22. Sun , S., Schiller , J.Gazdar, et al. A. Lung cancer in never smokers--a different disease. Nat Rev Cancer. 2007;7(10):778-90.
23. Patel , J., Bach, P., Kris M, et al.Lung cancer in US women: a contemporary epidemic. JAMA. 2004;291(14):1763-8.
24. Pietras , R., Márquez , D., Chen , H., et al. Estrogen and growth factor receptor interactions in human breast and non-small cell lung cancer cells. Steroids. 2005;70(5-7):372-81.
25. Bracke , M., Van Roy , F., Mareel , M, et al. The E-cadherin/catenin complex in invasion and metastasis. Curr Top Microbiol Immunol. 1996;213(Pt 1):123-61.
26. John , A., Tuszynski , G, et al. The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis. Pathol Oncol Res. 2001;7(1):14-23.
27. Liu, K., Zhang, J., Ren, J.-J, et al. Interference of human Na/K-ATPaseB1 subunit on proliferation. Chinese Journal of Cancer.2009;28(3):189-194.
28. Kuriyama, S., Yoshida , M., Yano , S, et al. LPP inhibits collective cell migration during lung cancer dissemination. 2016;35(8): 952-64.
29. Zhou, H., Zhang, Z., Liu , C, et al. B4GALT1 gene knockdown inhibits the hedgehog pathway and reverses multidrug resistance in the human leukemia K562/adriamycin-resistant cell line. IUBMB Life. 2012; 64(11):889-900.
30. Funato , K., Yamazumi , Y., Oda , T, et al. Tyrosine phosphatase PTPRD suppresses colon cancer cell migration in coordination with CD44. Exp Ther Med. 2011; 2(3):457-463.
31. Keita , M., Bachvarova , M., & Morin , C, et al. The RUNX1 transcription factor is expressed in serous epithelial ovarian carcinoma and contributes to cell proliferation, migration and invasion. Cell Cycle. 2013; 12(6):972-86.

32. Liu, D., Hu, J., Agorreta, J, et al.. Tumor necrosis factor receptor-associated protein 1(TRAP1) regulates genes involved in cell cycle and metastases. Cancer Lett. 2010;296(2):194-205.
33. Song, L., Chang, R.,Dai, C, et al. SORBS1 suppresses tumor metastasis and improves the sensitivity of cancer to chemotherapy drug. Oncotarget,2017;8(6): 9108-9122.
34. Kawakami, K., Fujita , Y., Kato , T, et al. Integrin β4 and vinculin contained in exosomes are potential markers for progression of prostate cancer associated with taxane-resistance. Int J Oncol. 2015; 47(1): 384-90.
35. Janes, K. A. When microarrays Met epidermal‐cell migration. Molecular Systems Biology. 2008.
36. LeaoM, AlexopoulouAN, CaballeroOL, et al. Dissecting the transcriptional networks underlying breast cancer: NR4A1 reduces the migration of normal and breast cancer cell lines. Breast Cancer Res. 2010 ;12(4).
37. Ma , Z., Qiu , X., Wang , D, et al. MiR-181a-5p inhibits cell proliferation and migration by targeting Kras in non-small cell lung cancer A549 cells. Acta Biochim Biophys Sin (Shanghai). 2015;47(8).
38. Liang , S., He , L., Zhao , X, et al. MicroRNA let-7f inhibits tumor invasion and metastasis by targeting MYH9 in human gastric cancer. PLoS One. 2011;6(4).

指導教授

蘇立仁(Li-Jen Su)

審核日期

2018-10-4

推文